PPCB supply chain intelligence for Propanc Biopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| UNIVERSITY-OF-BATH | UNIVERSITY-OF-BATH | 90% | In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2 … |
| UNIVERSITY-OF-JA-N | UNIVERSITY-OF-JA-N | 90% | On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company |
| 104-LLC | 104-LLC | 80% | Effective March 5, 2024, the Company entered into and closed a securities purchase agreement with 104 LLC |
| 1800-DIAGONAL | 1800-DIAGONAL | 80% | On July 22, 2025, the Company entered into and closed a securities purchase agreement with 1800 Diagonal, pursuant to which the 1800 Diagonal agreed to purchase a convertible promissory note from the… |
| GS-CAPITAL-PARTNERS-LLC | GS-CAPITAL-PARTNERS-LLC | 80% | On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company |
| AZN | AstraZeneca PLC | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from AZN grap… |
| KZIA | Kazia Therapeutics Limited | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| KZIA | Kazia Therapeutics Limited | 72% | Reciprocal relationship from KZIA graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from PPCB graph: novel expression system and are als… |
| LLY | Eli Lilly and Company | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from LLY grap… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant try… |
| MRK | Merck & Co., Inc. | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| OTLC | Oncotelic Therapeutics, Inc. | 72% | Reciprocal relationship from OTLC graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from OTLC graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from OTLC g… |
| OTLC | Oncotelic Therapeutics, Inc. | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant try… |
| AZN | AstraZeneca PLC | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| KZIA | Kazia Therapeutics Limited | 72% | Reciprocal relationship from KZIA graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant tr… |
| KZIA | Kazia Therapeutics Limited | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| LLY | Eli Lilly and Company | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant try… |
| MRK | Merck & Co., Inc. | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant try… |
| OTLC | Oncotelic Therapeutics, Inc. | 72% | Reciprocal relationship from OTLC graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant tr… |
| OTLC | Oncotelic Therapeutics, Inc. | 72% | novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic v… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PPCB-DEBT | Debt stack $573,873 | 90% | Market cache reports total debt of $573,873. |
| PPCB-DEBT-11866 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-06-30. |
| PPCB-DEBT-11865 | Warrants outstanding: 1000 | 90% | xbrl warrant detail from xbrl 2023-06-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PPCB-OWNER-UBS-GROUP-AG | UBS Group AG | 90% | 13F overlay lists UBS Group AG as top holder; 7 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MRK | Merck & Co., Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| KZIA | Kazia Therapeutics Limited | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 | |
| EXOZ | eXoZymes, Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 50.00 | 2 | |
| DKS | DICK'S Sporting Goods, Inc. | 50.00 | 2 | |
| IMMP | Immutep Limited | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 50.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 50.00 | 2 | |
| BNBX | BNB Plus Corp. | 50.00 | 2 | |
| PSNL | Personalis, Inc. | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 |